Cargando…

Gp41 and Gag amino acids linked to HIV‐1 protease inhibitor‐based second‐line failure in HIV‐1 subtype A from Western Kenya

INTRODUCTION: Failure of protease‐inhibitor (PI)‐based second‐line antiretroviral therapy (ART) with medication adherence but no protease drug resistance mutations (DRMs) is not well understood. This study investigated the involvement of gp41 and gag as alternative mechanisms, not captured by conven...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coetzer, Mia, Ledingham, Lauren, Diero, Lameck, Kemboi, Emmanuel, Orido, Millicent, Kantor, Rami
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Short Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5810327/ https://www.ncbi.nlm.nih.gov/pubmed/29098809 http://dx.doi.org/10.1002/jia2.25024

Ejemplares similares

Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya
por: Brooks, Katherine, et al.
Publicado: (2016)

885. HIV-1 Treatment Failure and Extensive Drug Resistance in Perinatally Infected Children Failing First-Line Antiretroviral Therapy in Western Kenya
por: Nyandiko, Winstone, et al.
Publicado: (2019)

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors
por: Manasa, Justen, et al.
Publicado: (2017)

Selection analyses of paired HIV-1 gag and gp41 sequences obtained before and after antiretroviral therapy
por: Tzou, Philip L., et al.
Publicado: (2018)

A Challenging Knowledge Gap: Estimating Modes of HIV Acquisition Among Adolescents Entering HIV Care During Adolescence
por: Humphrey, John, et al.
Publicado: (2022)

Neutralizing Antibodies Targeting HIV-1 gp41
por: Caillat, Christophe, et al.
Publicado: (2020)

gp41: HIV's shy protein
por: Zwick, Michael B, et al.
Publicado: (2004)

HIV diversity and drug resistance from plasma and non-plasma analytes in a large treatment programme in western Kenya
por: Kantor, Rami, et al.
Publicado: (2014)

2504. Laboratory Evaluation of HIV-1 Viral Load Pooling with Marker-Assisted Deconvolution
por: Holland, Sabina, et al.
Publicado: (2019)

Role of Gag in HIV Resistance to Protease Inhibitors
por: Clavel, François, et al.
Publicado: (2010)

2322. Challenges Faced by Perinatally-Infected Young People Living with HIV in Kenya During the COVID-19 Pandemic
por: Singh, Manjot, et al.
Publicado: (2023)

Convergent HIV-1 Evolution upon Targeted Destabilization of the gp120-gp41 Interface
por: Torrents de la Peña, Alba, et al.
Publicado: (2021)

Membrane topology analysis of HIV-1 envelope glycoprotein gp41
por: Liu, Shujun, et al.
Publicado: (2010)

Rational Design of A Novel Small-Molecule HIV-1 Inactivator Targeting Both gp120 and gp41 of HIV-1
por: Pu, Jing, et al.
Publicado: (2021)

Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs
por: Su, Chinh Tran-To, et al.
Publicado: (2019)

Striking HIV-1 Entry by Targeting HIV-1 gp41. But, Where Should We Target?
por: Teixeira, Cátia, et al.
Publicado: (2016)

Immunological Characterization of Plant-Based HIV-1 Gag/Dgp41 Virus-Like Particles
por: Kessans, Sarah A., et al.
Publicado: (2016)

P02-10. Plant expression of chimeric Gag/gp41 virus-like particles as a mucosally-targeted subunit vaccine against HIV-1
por: Kessans, SA, et al.
Publicado: (2009)

Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41
por: Sanders, Rogier W, et al.
Publicado: (2004)

HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions
por: Qi, Qianqian, et al.
Publicado: (2017)

Enhancing Exposure of HIV-1 Neutralization Epitopes through Mutations in gp41
por: Blish, Catherine A, et al.
Publicado: (2008)

Asymmetric Deactivation of HIV-1 gp41 following Fusion Inhibitor Binding
por: Kahle, Kristen M., et al.
Publicado: (2009)

Approaches for Identification of HIV-1 Entry Inhibitors Targeting gp41 Pocket
por: Yu, Fei, et al.
Publicado: (2013)

HIV Gag and PR: partners in resistance to protease and maturation inhibitors
por: Nijhuis, Monique
Publicado: (2011)

FRET analysis of HIV‐1 Gag and GagPol interactions
por: Takagi, Shimon, et al.
Publicado: (2017)

A Clinical Decision Support System for Integrating Tuberculosis and HIV Care in Kenya: A Human-Centered Design Approach
por: Catalani, Caricia, et al.
Publicado: (2014)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Analysis of gp41 epitopes in model viral membranes to study HIV-1 neutralization
por: Reichart, T, et al.
Publicado: (2012)

Modulation of Cytokine Release and Gene Expression by the Immunosuppressive Domain of gp41 of HIV-1
por: Denner, Joachim, et al.
Publicado: (2013)

HIV-1 Envelope gp41 Broadly Neutralizing Antibodies: Hurdles for Vaccine Development
por: Verkoczy, Laurent, et al.
Publicado: (2014)

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
por: Huang, Jinghe, et al.
Publicado: (2012)

Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer
por: Khasnis, Mukta D., et al.
Publicado: (2016)

Structure of HIV-1 gp41 with its membrane anchors targeted by neutralizing antibodies
por: Caillat, Christophe, et al.
Publicado: (2021)

Subtype-specific differences in Gag-protease replication capacity of HIV-1 isolates from East and West Africa
por: Farinre, Omotayo, et al.
Publicado: (2021)

Added Value of Next Generation Sequencing in Characterizing the Evolution of HIV-1 Drug Resistance in Kenyan Youth
por: Novitsky, Vlad, et al.
Publicado: (2023)

Effects of the COVID-19 pandemic on late postpartum women living with HIV in Kenya
por: Humphrey, John M., et al.
Publicado: (2023)

Biological and biochemical characterization of HIV-1 Gag/dgp41 virus-like particles expressed in Nicotiana benthamiana
por: Kessans, Sarah A, et al.
Publicado: (2013)

Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity
por: Pincus, Seth H., et al.
Publicado: (2021)

Conserved positive selection signals in gp41 across multiple subtypes and difference in selection signals detectable in gp41 sequences sampled during acute and chronic HIV-1 subtype C infection
por: Bandawe, Gama P, et al.
Publicado: (2008)

HIV-1 gp41 Core with Exposed Membrane-Proximal External Region Inducing Broad HIV-1 Neutralizing Antibodies
por: Wang, Ji, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_p4eu9llhumeim0g3sq1r5rv6gl